EntreChem SL is the only company in the world using synthetic biology, combinatorial biosynthesis and biocatalysis to develop new natural products with drug candidates close to clinical trials.
- Our technology allows development of complex bioactive small molecules not possible by other strategies, leading to the development of novel, IP protected molecules, through composition of matter and use patents.
- Natural products are privileged structures designed by nature to interact with many targets, a feature especially relevant in cancer, where malignant cells escape death through multiple mechanisms.
- The promise of “polypharmacology in a single drug” is closer to clinical realization, since our drugs address relevant multiple targets and pathways, both in tumor and cancer stem cells, avoiding the additive toxicity of chemotherapy combinations, the current treatment modality.
We are a biotechnology company founded as a spin-off of the University of Oviedo (Spain), and led by its cofounder Francisco Morís PhD, and supported by collaborations with leading cancer scientists in Europe and the USA, as well as by experienced U.S. and European Business Development professionals.
